SCHEMBL277913

SCHEMBL277913

CCOCCC(=O)NCCS

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
HDAC3 O15379 6/20 0.41
HDAC4 P56524 6/20 0.41
HDAC1 Q13547 6/20 0.41
HDAC7 Q8WUI4 6/20 0.41
HDAC2 Q92769 6/20 0.41
HDAC10 Q969S8 6/20 0.41
HDAC11 Q96DB2 6/20 0.41
HDAC8 Q9BY41 6/20 0.41
HDAC6 Q9UBN7 6/20 0.41
HDAC9 Q9UKV0 6/20 0.41
HDAC5 Q9UQL6 6/20 0.41
TSHR P16473 3/20 0.40
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CASP2 P42575 1/20 0.37
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16309409 0.85 SMN1; SMN2 (0.44) SMN1; SMN2HDAC3HDAC4HDAC1HDAC7
SCHEMBL2119757 0.84 SMN1; SMN2 (0.46) SMN1; SMN2TSHRRAB9AALDH1A1CASP2
SCHEMBL5836462 0.82 CNR1 (0.46) SMN1; SMN2ALDH1A1
SCHEMBL13073508 0.81 SMN1; SMN2 (0.42) SMN1; SMN2TSHRRAB9AALDH1A1
SCHEMBL14524402 0.81 TSHR (0.50) SMN1; SMN2HDAC3HDAC4HDAC1HDAC7
SCHEMBL24943529 0.81 SMN1; SMN2 (0.44) SMN1; SMN2TSHRRAB9AALDH1A1CASP2
SCHEMBL16133369 0.81 CASP2 (0.55) SMN1; SMN2TSHRCASP2DNM1
SCHEMBL23711864 0.81 SMN1; SMN2 (0.44) SMN1; SMN2TSHRRAB9AALDH1A1CASP2
SCHEMBL12412458 0.81 SMN1; SMN2 (0.44) SMN1; SMN2TSHRRAB9AALDH1A1CASP2
SCHEMBL25680587 0.79 FAAH (0.48) SMN1; SMN2TSHRRAB9AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9763995-B2 Polymer conjugates of protegrin peptides NEKTAR THERAPEUTICS (US) 2017-09-19 US disclosed
US-20170196975-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY NEKTAR THERAPEUTICS 2017-07-13 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-9636412-B2 Conjugates of an anti-TNF-alpha antibody NEKTAR THERAPEUTICS (US) 2017-05-02 US disclosed
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-9446139-B2 Polymer-based compositions and conjugates of HIV entry inhibitors NEKTAR THERAPEUTICS (US) 2016-09-20 US disclosed
US-9433684-B2 Conjugates of small-interfering nucleic acids NEKTAR THERAPEUTICS (US) 2016-09-06 US disclosed
US-20160175402-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS 2016-06-23 US disclosed
US-20160158311-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES NEKTAR THERAPEUTICS 2016-06-09 US disclosed
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 US disclosed
US-20100120982-A1 POLYMER-FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-13 US disclosed
US-7714114-B2 Conjugates of an EPO moiety and a polymer NEKTAR THERAPEUTICS (US) 2010-05-11 US disclosed
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY NEKTAR THERAPEUTICS (US) 2010-01-28 US disclosed
US-20090280550-A1 Polymer-Factor IX Moiety Conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-11-12 US disclosed
US-7579444-B2 Polymer-factor IX moiety conjugates NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-08-25 US disclosed
US-20090041714-A1 Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-02-12 US disclosed
US-20080058504-A1 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor NEKTAR THERAPEUTICS 2008-03-06 US disclosed
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer NEKTAR THERAPEUTICS 2007-04-26 US disclosed
US-7199223-B2 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090041714-A1 Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia F13B, F8, F13A1 SMN1; SMN2 3568/4885HDAC3 2536/4885HDAC4 2498/4885
US-20100120689-A1 POLYMER FACTOR VIII MOIETY CONJUGATES F8, F9, F13B SMN1; SMN2 1435/4885HDAC3 3158/4885HDAC4 3660/4885
US-20170035896-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 SMN1; SMN2 2365/4885HDAC3 1558/4885HDAC4 3492/4885
US-20100120982-A1 POLYMER-FACTOR IX MOIETY CONJUGATES F9, F13A1, F13B SMN1; SMN2 2381/4885HDAC3 1786/4885HDAC4 3512/4885
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY TNF, TNFRSF1A, TNFRSF9 SMN1; SMN2 2077/4885HDAC3 3669/4885HDAC4 4506/4885
US-20170196975-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY TNF, TNFRSF1A, TNFRSF9 SMN1; SMN2 1898/4885HDAC3 3354/4885HDAC4 4375/4885
US-20160158311-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES PSMG3, PSMB11, UBQLN1 SMN1; SMN2 1248/4885HDAC3 4181/4885HDAC4 4582/4885
US-20160175402-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B SMN1; SMN2 1402/4885HDAC3 3212/4885HDAC4 3625/4885
US-20070092482-A1 Conjugates of a G-CSF moiety and a polymer CSF3R, GMFG, CSF1R SMN1; SMN2 1544/4885HDAC3 3159/4885HDAC4 3722/4885
US-20080058504-A1 Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor F8, F13A1, F13B SMN1; SMN2 3529/4885HDAC3 3082/4885HDAC4 3523/4885
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER IL15, IL15RA, IL2 SMN1; SMN2 4077/4885HDAC3 1846/4885HDAC4 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.